Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...
As an individual, Kamakoti has his right to hold his belief and practise it. But he should not publicly endorse a controversial claim that has been dismissed by the scientific and medical community.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback